IP and innovative companies: the case of PerceivAI

Published on April 15, 2024

With the support of momentumPI, the innovative company PerceivAI was able to protect its intellectual property, including its trademark and technology, in a context where it wishes to sell licenses for use to pharmaceutical companies.

PerceivAI - photo by Christian Dansereau

It is particularly expensive to develop treatments for certain diseases, such as Alzheimer's disease, because the effects of these treatments can vary greatly from one patient to another.

Montreal-based startup Perceiv AI has designed a platform that makes it possible to better anticipate these effects, thereby accelerating drug development and treatments.

[…]

Perceiv AI's business model is to sell pharmaceutical companies a license to use its service for the duration of a clinical trial.

The start-up counts Montreal-based DalCor Pharmaceuticals among its clients. It has also formed partnerships with major American pharmaceutical companies Merck and Johnson & Johnson.

–

This content is taken from an article in InfoBref about the momentumPI service.

Curious to read more on the subject?

Visit the InfoBref website to read the full article.